Evolocumab

Drug Profile

Evolocumab

Alternative Names: AMG-145; Repatha

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Amgen Astellas BioPharma
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 15 Sep 2017 New safety and efficacy data from the phase III FOURIER trial in Hypercholesterolaemia released by Amgen
  • 05 Sep 2017 Amgen completes a phase III trial in Hypercholesterolaemia (Adjunctive treatment) in USA, Spain, Mexico, Italy, Canada, Belgium, Poland (SC) (NCT02739984)
  • 30 Aug 2017 Amgen Astellas receives marketing approval for 420 mg evolocumab, for Hypercholesterolemia in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top